Michael Kalos | Chief Scientific Officer, Cancer Immunobiology
Eli Lilly and Co

Michael Kalos, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Co

Dr. Kalos is a member of Lilly’s Research Oncology Division, where as part of the senior leadership he leads preclinical and translational efforts in Cancer Immunotherapy.  Dr. Kalos is a recognized international key thought leader in the fields of immunotherapy, cellular therapy, and biomarkers, with over 20 years experience spanning biotech, academia, and big pharma.  He has authored multiple high-impact primary and review articles as well as book chapters in the field of cancer immunotherapy, has been an invited speaker at national and international scientific meetings, is a member of institutional and corporate scientific advisory boards, and steering committees for international  immunotherapy societies and working groups.


EAC 2017 Day 1, Tuesday 31st October 2017 @ 09:05

Keynote: Combination strategies in Immuno-oncology: the future is now

  • First generation immunotherapies highlight the promise of harnessing the immune system to target cancer, but most patients do not receive durable benefit
  • The complexity of the immune system and cancer interphase necessitates the development of combination therapies 
  • Development of rational combination therapies requires deep understanding of both the disease and the immunological landscape of patients 

EAC 2017 Day 2, Wednesday 1st November 2017 @ 09:05

Keynote Panel: Oncology strategies across pharma

  • High level pharma companies come together to discuss their strategies for tackling cancer
  • Each company will give a 5-minute presentation on their strategy, and a fire side discussion on oncology focused strategies will follow
  • Strategies will cover cytotherapy, checkpoint inhibitors, combination therapy, sequential therapy, approaches to solid tumours, treatments and diagnostics

back to speakers